Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections

Rujipas Sirijatuphat; Visanu Thamlikitkul

doi:10.1128/AAC.02435-13

Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections

Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601. doi: 10.1128/AAC.02435-13. Epub 2014 Jun 30.

Authors

Rujipas Sirijatuphat¹, Visanu Thamlikitkul²

Affiliations

¹ Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
² Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand [email protected].

Abstract

Ninety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.).

Publication types

Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Acinetobacter Infections / drug therapy*
Acinetobacter Infections / microbiology
Acinetobacter Infections / mortality
Acinetobacter baumannii / drug effects*
Aged
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Carbapenems / therapeutic use
Colistin / adverse effects
Colistin / therapeutic use*
Cross Infection / drug therapy
Cross Infection / microbiology
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Female
Fosfomycin / adverse effects
Fosfomycin / therapeutic use*
Humans
Male
Microbial Sensitivity Tests
Pilot Projects
Treatment Outcome

Substances

Anti-Bacterial Agents
Carbapenems
Fosfomycin
Colistin

Associated data

ClinicalTrials.gov/NCT01297894